SWTX SpringWorks Therapeutics Inc
Price (delayed)
$46.52
Market cap
$3.49B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.48
Enterprise value
$3.42B
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks
Highlights
SpringWorks Therapeutics's revenue has increased by 41% from the previous quarter
The gross profit has grown by 40% from the previous quarter
SWTX's quick ratio is down by 43% year-on-year and by 39% since the previous quarter
SpringWorks Therapeutics's equity has decreased by 23% YoY and by 10% QoQ
Key stats
What are the main financial stats of SWTX
Market
Valuations
Earnings
Shares outstanding
74.94M
Market cap
$3.49B
Enterprise value
$3.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.19
Price to sales (P/S)
18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.87
Revenue
$191.59M
Gross profit
$179.04M
Operating income
-$278.13M
Net income
-$258.13M
EBIT
-$258.13M
EBITDA
-$252.88M
Free cash flow
-$180.05M
Per share
Balance sheet
Liquidity
EPS
-$3.48
EPS diluted
-$3.48
Free cash flow per share
-$2.43
Book value per share
$6.47
Revenue per share
$2.58
TBVPS
$7.92
Total assets
$587.28M
Total liabilities
$106.17M
Debt
$7.91M
Equity
$481.1M
Working capital
$280.48M
Debt to equity
0.02
Current ratio
3.81
Quick ratio
3.55
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-132%
Gross margin
93.4%
Net margin
-134.7%
Operating margin
-145.2%
Return on assets
-41.8%
Return on equity
-48.3%
Return on invested capital
-55.8%
Return on capital employed
-53%
Return on sales
-134.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SWTX stock price
How has the SpringWorks Therapeutics stock price performed over time
Intraday
11.08%
1 week
0.09%
1 month
-19.46%
1 year
0.5%
YTD
28.76%
QTD
5.42%
Financial performance
How have SpringWorks Therapeutics's revenue and profit performed over time
Revenue
$191.59M
Gross profit
$179.04M
Operating income
-$278.13M
Net income
-$258.13M
Gross margin
93.4%
Net margin
-134.7%
SWTX's net margin has surged by 98% year-on-year and by 34% since the previous quarter
SWTX's operating margin has soared by 98% YoY and by 33% from the previous quarter
SpringWorks Therapeutics's revenue has increased by 41% from the previous quarter
The gross profit has grown by 40% from the previous quarter
Growth
What is SpringWorks Therapeutics's growth rate over time
Valuation
What is SpringWorks Therapeutics stock price valuation
P/E
N/A
P/B
7.19
P/S
18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.87
SWTX's EPS is up by 32% YoY and by 11% from the previous quarter
SpringWorks Therapeutics's equity has decreased by 23% YoY and by 10% QoQ
The P/B is 22% above the 5-year quarterly average of 5.3 and 20% above the last 4 quarters average of 5.4
SWTX's P/S is 68% below its last 4 quarters average of 50.3
SpringWorks Therapeutics's revenue has increased by 41% from the previous quarter
Efficiency
How efficient is SpringWorks Therapeutics business performance
SWTX's ROS has soared by 98% YoY and by 34% from the previous quarter
The company's return on invested capital rose by 31% YoY and by 3.5% QoQ
SWTX's ROA is up by 27% YoY
The ROE has grown by 26% YoY
Dividends
What is SWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SWTX.
Financial health
How did SpringWorks Therapeutics financials performed over time
SWTX's quick ratio is down by 43% year-on-year and by 39% since the previous quarter
The company's current ratio fell by 41% YoY and by 38% QoQ
SWTX's debt is 98% smaller than its equity
The debt to equity has soared by 100% from the previous quarter and by 100% YoY
SpringWorks Therapeutics's equity has decreased by 23% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.